LSD1 inhibition not only inhibited tumor growth but specifically targeted those elements of the tumor that promote progression and therapeutic resistance, i.e., mesenchymal and stem-like cells and metastatic disease (Figures 2B,C). Here, KDM1A is linked to neoplasm.